Rochester, NY 7/16/2009 8:24:18 AM
ARYX - Clinical Trial EmbraceAC Results Announced by ARYx Therapeutics
ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc., ARYX
WhisperFromWallStreet.com offers daily stock alerts to subscribers. Sign up for our free alerts newsletter.
ARYx Therapeutics, Inc. announced that results from its Phase 2/3 clinical trial, EmbraceAC, comparing its novel anticoagulant agent tecarfarin (previously ATI-5923) with the leading oral anticoagulant warfarin. In this trial, tecarfarin demonstrated efficacy essentially the same as in earlier Phase II studies but did not achieve the primary endpoint of superiority over warfarin, as measured by time in therapeutic range (TTR).
About WhisperFromWallStreet.com
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert.
Sign up for our FREE alerts newsletter at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
